Key result
Benidipine significantly reduced the risk of major adverse cardiovascular events (HR 0.41) compared to other treatments in Japanese patients with vasospastic angina.
Why the study?
Does benidipine reduce major adverse cardiovascular events in Japanese patients with vasospastic angina compared to other calcium channel blockers?
Meta-Analysis (n=1,997)
Does benidipine reduce major adverse cardiovascular events in Japanese patients with vasospastic angina compared to other calcium channel blockers?
Hazard Ratio: 0.41 (95% CI 0.2–0.85)
p-value: p=0.016
In Japanese patients with vasospastic angina, treatment with benidipine was associated with a significantly lower risk of major adverse cardiovascular events compared to other calcium channel blockers.
No takes yet. Share an insight, caveat, or question.
May favor benidipine in Japanese vasospastic angina; leaves open randomized confirmation before practice change.
Nishigaki et al. (2010) conducted a meta-analysis in Vasospastic angina (n=1,997). Benidipine vs. Other calcium channel blockers (amlodipine, nifedipine, diltiazem) or no benidipine was evaluated on Major adverse cardiovascular events (MACE) (HR 0.41, 95% CI 0.20-0.85, p=0.016). Benidipine significantly reduced the risk of major adverse cardiovascular events (HR 0.41) compared to other treatments in Japanese patients with vasospastic angina.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: